This clinical trial is focused on studying the treatment of Pseudomonas aeruginosa bacteremia, a type of blood infection caused by the bacteria Pseudomonas aeruginosa. The study aims to determine if a shorter, 7-day course of antibiotics is more effective and safer compared to the traditional 14-day course. The antibiotics being studied include Meropenem, Aztreonam, Levofloxacin, Amikacin, Colistimethate Sodium, Ciprofloxacin, Ceftazidime, Tobramycin, Imipenem, Cilastatin, Piperacillin, Tazobactam, Cefiderocol, Avibactam, Vaborbactam, and Delafloxacin. Some of these medications are given as injections or infusions, while others are taken orally as tablets.
The purpose of the study is to evaluate whether the shorter treatment can effectively treat the infection while reducing the risk of serious side effects and minimizing the exposure to antibiotics. Participants in the study will be randomly assigned to receive either the 7-day or 14-day antibiotic treatment. The study will monitor the participants’ health and recovery over a period of time, checking for any recurrence of the infection, side effects, or other health issues.
Throughout the study, the effectiveness of the treatment will be assessed using a method called the DOOR/RADAR analysis, which helps in ranking the outcomes based on their desirability. The study will also track the number of days participants need antibiotics and their overall health status at the end of the follow-up period. This research aims to provide valuable insights into optimizing antibiotic use for treating Pseudomonas aeruginosa bacteremia, potentially leading to improved treatment guidelines in the future.
Spain 
